Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Ewing Sarcoma of Bone Clinical Trial

Official title:

A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents With an Interval Compression Schedule in Newly Diagnosed Patients With Localized Ewing Sarcoma Family of Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00618813
• Other study ID #: AEWS07P1
• Secondary ID: NCI-2009-00371CD
• Status: Completed
• Phase: N/A
• First received: February 19, 2008
• Last updated: September 11, 2014
• Start date: March 2008

Study information

• Verified date: September 2014
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.

Description:

PRIMARY OBJECTIVES:

I. To assess the feasibility and safety of adding interval-compressed vincristine, topotecan hydrochloride, and cyclophosphamide to a treatment protocol utilizing interval compression of vincristine, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide in patients with localized Ewing sarcoma family of tumors.

SECONDARY OBJECTIVES:

I. To estimate the event-free survival in patients treated with this regimen.

OUTLINE: This is a multicenter study.

INDUCTION THERAPY (WEEKS 1-12): Patients receive vincristine IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11, and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 1 hour on days 1-5 in weeks 1 and 9 and on day 1 in weeks 5 and 11; ifosfamide IV over 1 hour on days 1-5 in weeks 3 and 7; etoposide IV over 1 hour on days 1-5 in weeks 3 and 7; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 5 and 11. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning 24-36 hours after the last dose of chemotherapy and continuing for at least 7 days or until blood counts recover, whichever comes last. Filgrastim is discontinued at least 24 hours prior to the next course of chemotherapy.

LOCAL CONTROL: Patients who respond to induction therapy may undergo surgery alone if the lesion can be resected with negative margins and with a reasonable functional result beginning in week 13. Following surgery, patients with unresectable lesions or inadequate margins may receive radiotherapy during week 15. Patients with bulky lesions in surgically difficult sites such as the spine, skull, and periacetabular pelvis; poor response to induction chemotherapy; or those in whom surgery would result in unacceptable functional results may receive radiotherapy alone in weeks 13-19. Patients with bulky lesions in difficult sites and who do not have a good clinical and radiographic response to induction therapy may receive radiotherapy to the primary site during weeks 13-19 followed by surgery of the involved site during week 25 after recovery from course 11 of chemotherapy. Patients with microscopic residual disease after planned pre-operative radiotherapy will receive additional radiotherapy.

CONTINUATION THERAPY (WEEKS 15-36): Patients receive vincristine IV on day 1 in weeks 15, 16, 21-24, 27-30, 33, and 34; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 15, 21, and 29; cyclophosphamide IV over 1 hour on days 1-5 in weeks 15, 21 and 29 and on day 1 in weeks 23, 27, and 33; ifosfamide IV over 1 hour on days 1-5 in weeks 17, 19, 25, 31, and 35; etoposide IV over 1 hour on days 1-5 in weeks 17, 19, 25, 31, and 35; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 of weeks 23, 27, and 33. Patients also receive G-CSF SC as in induction therapy.

After completion of study treatment, patients are followed for 10 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 30 Years

Eligibility

Inclusion Criteria:

• Diagnosis of extracranial Ewing sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue:

• Newly diagnosed disease

• Disease confirmed by biopsy only with no attempt at complete or partial resection

• Unplanned excision allowed provided adequate imaging was obtained prior to surgery and incompletely resected disease is controlled by local therapy

• No esthesioneuroblastoma

• Localized disease, including any of the following sites:

• Chest wall tumors with ipsilateral pleural effusions, ipsilateral positive pleural fluid cytology, or ipsilateral pleural based secondary tumor nodules;

• No contralateral pleural effusions or pleural nodules

• Regional lymph nodes that are clinically suspicious or confirmed by biopsy

• No distant lymph node metastases

• Extra-dural tumors arising in the bony skull

• No tumors arising in the intra-dural soft tissue or the intra-dural region of the spine

• No evidence of metastatic disease, defined as any of the following:

• Lesions that are discontinuous from the primary tumor

• Lesions that are not regional lymph nodes

• Lesions that do not share a body cavity with the primary tumor

• No evidence by CT scan of metastatic lung disease, defined as any of the following:

• One pulmonary nodule > 1 cm in diameter or more than one nodule > 0.5 cm diameter

• Pulmonary nodules that are resected and are not found to be metastatic Ewing sarcoma are allowed

• Biopsy proven solitary nodules measuring 0.5 to 1.0 cm or multiple nodules measuring 0.3 to 0.5 cm

• Solitary nodules measuring < 0.5 cm or multiple nodules measuring < 0.3 cm are allowed unless biopsy proven to be metastatic (biopsy is not required)

• Karnofsky performance status (PS) 0-2 (>= 16 years old) OR Lansky PS 0-2 (< 16 years old)

• Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR serum creatinine based on age/gender as follows:

• 1 month to < 6 months old (males and females 0.4 mg/dL)

• 6 months to < 1 year old (males and females 0.5 mg/dL)

• 1 to < 2 years old (males and females 0.6 mg/dL)

• 2 to < 6 years old (males and females 0.8 mg/dL)

• 6 to < 10 years old (males and females 1.0 mg/dL)

• 10 to < 13 years old (males and females 1.2 mg/dL)

• 13 to < 16 years old (males 1.5 mg/dL and females 1.4 mg/dL)

• >= 16 years old (males 1.7 mg/dL and females 1.4 mg/dL)

• AST or ALT < 2.5 times ULN for age

• Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

• Shortening fraction of >= 27% by ECHO or ejection fraction of >= 50% by radionuclide angiogram (MUGA)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No prior chemotherapy or radiotherapy

• No concurrent pegfilgrastim (Neulasta) or sargramostim (GM-CSF)

• No other concurrent cancer chemotherapy or immunomodulating agents, including steroids, unless used as an antiemetic

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ewing Sarcoma of Bone
• Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Neuroectodermal Tumors, Primitive, Peripheral
• Sarcoma
• Sarcoma, Ewing

Intervention

Other:
• radiation therapy
Undergo radiation therapy
• therapeutic conventional surgery
Undergo surgery

Drug:
• etoposide
Given IV
• ifosfamide
Given IV
• doxorubicin hydrochloride
Given IV
• cyclophosphamide
Given IV
• vincristine sulfate
Given IV
• topotecan hydrochloride
Given IV

Biological:
• filgrastim
Given SC

Locations

Country	Name	City	State
United States	Children's Oncology Group	Monrovia	California

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Death	Incidence of death from complications of therapy while the patient is on protocol therapy or within one month of terminating protocol therapy	Length of protocol therapy (up to 37 weeks) plus 30 days	Yes
Primary	Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Enrollment to Week 12	The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks.	Enrollment to week 12	Yes
Primary	Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 13 to Week 22	The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks.	Week 13 to week 22	Yes
Primary	Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 23 to Week 28	The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks.	Week 23 to week 28	Yes
Primary	Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 29 to Week 37	The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks.	Week 29 to week 37	Yes
Secondary	Event Free Survival	Disease progression, occurrence of a second malignant neoplasm (SMN)or death will be considered an analytic event. In all other cases, the patient will be considered censored at last contact.	From enrollment to event or 10 years from enrollment, whichever occurs first	No